Analogous Oseltamivir Phosphate Capsules — Competitive Intelligence Brief

Analogous Oseltamivir Phosphate Capsules (Analogous Oseltamivir Phosphate Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuraminidase inhibitor. Area: Infectious Disease.

phase 2 Neuraminidase inhibitor Neuraminidase Infectious Disease Small molecule

Target snapshot

Analogous Oseltamivir Phosphate Capsules (Analogous Oseltamivir Phosphate Capsules) — Dalian Zhen-Ao Bio-Tech Co., Ltd.. Oseltamivir Phosphate is a neuraminidase inhibitor, targeting the influenza virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Analogous Oseltamivir Phosphate Capsules TARGET	Analogous Oseltamivir Phosphate Capsules	Dalian Zhen-Ao Bio-Tech Co., Ltd.	phase 2	Neuraminidase inhibitor	Neuraminidase
Oseltamivir(oral)	Oseltamivir(oral)	Guangdong Raynovent Biotech Co., Ltd	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Flu Vaccine	Flu Vaccine	La Fundacion Favaloro para la Investigacion y la Docencia Medica	marketed	Prophylactic vaccine	Influenza A and B viral hemagglutinin and neuraminidase surface antigens
Tamiflu®	Tamiflu®	Genuine Research Center, Egypt	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Oseltamivir phosphate granules	Oseltamivir phosphate granules	China Academy of Chinese Medical Sciences	marketed	Neuraminidase inhibitor	Influenza neuraminidase
zanamivir for inhalation	zanamivir for inhalation	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuraminidase inhibitor class)

1. University of Oxford · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Guangdong Raynovent Biotech Co., Ltd · 2 drugs in this class
4. UMC Utrecht · 2 drugs in this class
5. Genuine Research Center, Egypt · 1 drug in this class
6. The First Affiliated Hospital of Guangzhou Medical University · 1 drug in this class
7. China Academy of Chinese Medical Sciences · 1 drug in this class
8. Hoffmann-La Roche · 1 drug in this class
9. National Institute for Public Health and the Environment (RIVM) · 1 drug in this class
10. The Affiliated Hospital of Qingdao University · 1 drug in this class